News | May 31, 2025
QMS Medical Allied Services posts 134.36% jump in consolidated PAT in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
EBITDA for the period rose by 23.2% to Rs. 3,797 million
CRL shall invest another Rs. 200 crore for creation of additional beds
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Topiramate is indicated as a treatment of epilepsy and migraine
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The closing of the Block Acquisition is now expected to be completed by Q3 2025
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
Subscribe To Our Newsletter & Stay Updated
